• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Forest Laboratories to Acquire Clinical Data

Forest Laboratories to Acquire Clinical Data

March 1, 2011
CenterWatch Staff

Buyout speculation fueled by the late-January approval of depression drug Viibryd (vilazodone) ended last week as Clinical Data of Newton, Mass., disclosed an offer much lower than analysts had expected, reported BioWorld Week.

Buyer Forest Laboratories of New York, which is shelling out $30 per share, or about $1.2 billion in cash up front, for the biotech, is a perfect home for Viibryd. Forest already markets Lexapro (escitalopram oxalate), an SSRI, which raked in sales of $586.5 million for the last three months of 2010. Viibryd could help offset declining sales of Lexapro after it starts losing patent protection next year.

Piper Jaffray analyst David Amsellem called it a “Hail Mary pass [that] falls incomplete.” Given the crowded depression market and the number of generics available, “we have a difficult time envisioning blockbuster potential for Viibryd.”

Forest agreed to pay another $6 per share if certain 12-month sales targets are hit: $1 per share if Viibryd reaches $800 million in sales within five years; $2 per share if sales meet or exceed $1.1 billion within six years; and $3 per share if sales reach at least $1.5 billion in seven years.

Though Forest also picks up rights to stress imaging agent Stedivaze (apadenoson), the value of the Clinical Data acquisition hinges on Viibryd’s commercial potential. A dual-acting SSRI and 5HT1A partial agonist, the drug could stack up well as an alternative to traditional SSRIs and erotonin/norepinephrine reuptake inhibitors. Many patients do not respond to treatment with those drugs, and Viibryd’s safety profile—fewer weight gain and sexual side effects—might be enough of an advantage to garner a nice share of the $12 billion antidepressant market.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing